Dose-Dense Biweekly Doxorubicin/Docetaxel Versus Sequential Neoadjuvant Chemotherapy with Doxorubicin/Cyclophosphamide/Docetaxel in Operable Breast Cancer: Second Interim Analysis
- 1 October 2002
- journal article
- clinical trial
- Published by Elsevier BV in Clinical Breast Cancer
- Vol. 3 (4), 276-280
- https://doi.org/10.3816/cbc.2002.n.031
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With DocetaxelJournal of Clinical Oncology, 2002
- Preoperative Chemotherapy in Primary Operable Breast Cancer: Results From the European Organization for Research and Treatment of Cancer Trial 10902Journal of Clinical Oncology, 2001
- Preoperative (neoadjuvant) chemotherapy in patients with breast cancerSeminars in Oncology, 2001
- Maximized Reduction of Primary Breast Tumor Size Using Preoperative Chemotherapy With Doxorubicin and DocetaxelJournal of Clinical Oncology, 1999
- Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant ChemotherapyJournal of Clinical Oncology, 1999
- A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity.Journal of Clinical Oncology, 1998
- Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.Journal of Clinical Oncology, 1998
- Primary Chemotherapy in Breast CancerAmerican Journal of Clinical Oncology, 1998
- Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.Journal of Clinical Oncology, 1997